OPPORTUNITY-PLUS INVESTMENT FUND
Transforming Immunotheraphy
Leading the Future of Precision Immunotherapy
Implicit Bioscience Ltd is a clinical-stage drug development company headquartered in Brisbane, Australia, with two wholly owned subsidiaries—Line 6 Biotechnology, Inc and Implicit Bioscience, Inc—based in Seattle, USA. Founded in 2004 by experienced industry professionals, the company is committed to advancing novel immunomodulatory therapies with a strong development team across life sciences, legal, research, and finance sectors. This people-centered approach reflects the principle that quality talent drives value creation for patients and investors alike.
OVERVIEW
Founded in 2004, Implicit Bioscience is a privately held, clinical-stage biopharmaceutical company headquartered in Brisbane, Australia, with a wholly owned U.S. subsidiary based in Seattle, Washington. The company is focused on developing novel immunotherapies that target the innate immune system to treat serious neurological and inflammatory diseases. With operations spanning both Australia and the United States, Implicit Bioscience combines global research capabilities with a translational approach to drug development.
The company’s lead asset, IC14, is a monoclonal antibody that targets CD14, a key innate immune receptor involved in the body’s inflammatory response. IC14 is currently in clinical trials for amyotrophic lateral sclerosis (ALS) and acute respiratory distress syndrome (ARDS), among other indications. Implicit Bioscience’s core strength lies in its deep expertise in immunology and its commitment to advancing first-in-class therapies that address conditions with high unmet medical need.
LEAD THERAPEUTIC PROGRAM:
IC14 (atibuclimab)
IC14 is an investigational anti‑CD14 monoclonal antibody designed to block CD14, a key upstream regulator of the immune response. It is the only clinical‑stage therapeutic focused on this mechanism. IC14 is being evaluated across multiple therapeutic areas including motor neurone disease (MND), amyotrophic lateral sclerosis (ALS), cardioimmunology, and all‑cause acute respiratory distress syndrome (ARDS)
THE OPPORTUNITY
The opportunities that Implicit Bioscience provides:
First-in-Class Therapy
IC14 is the only clinical-stage monoclonal antibody targeting CD14,
a critical immune system regulator involved in multiple
high-burden diseases.
Multiple High-Value Indications
IC14 is being evaluated in cardiology, respiratory, and neuroscience conditions including heart failure,
ARDS, ALS/MND, and stroke—each representing multibillion-dollar markets.
FDA-Approved Clinical Programs
The company has received multiple FDA approvals for clinical trials, including in acute decompensated
heart failure and ALS, demonstrating strong regulatory momentum.
Positive Early Clinical Data
Initial trial results in heart failure patients have shown rapid and sustained clinical
improvements with no safety signals after a single dose of IC14.
Strong Precision Medicine Strategy
Implicit is integrating biomarkers like presepsin and partnering with Panasonic Healthcare to develop rapid
diagnostic tools, enhancing treatment targeting and value.
STRATEGIC OUTLOOK
Implicit Bioscience is uniquely positioned to deliver significant value through:
PROGRESSION
of IC14 into key clinical trials across multiple high‑need disease areas
EXPANSION
of its pipeline with broad-spectrum, first-in-class biologics targeting CD14
OPPORTUNITY
Opportunity for strategic partnerships with pharmaceutical
companies seeking innovation in immunomodulatory therapies
WORLD CLASS LEADERSHIP
Meet the innovative minds behind Implicit Bioscience.
PETER ANDREWS
FTSE FAICD Chairman
Garry Redlich
BA LLB DUniv
CEO and Managing Director
PETER Fry
BSc
Non-Executive Director
Stephen st baker
BAppSc
MAICD Non-Executive Director
Trevor st baker
Alternate Director for Stephen St Baker
lee hunstman
Non-Executive Director
dr. stephen hoffman
PhD MD. Non-Executive Director
Learn more.
To learn more about Implicit Bioscience and their innovations, visit their website below.
Implicit Bioscience Supplementary Information Memorandum
This document serves as the primary information memorandum for Implicit Bioscience, providing key details about the company's business model, operations, investment structure, and associated risks. It outlines the terms of the investment opportunity and is intended to support informed decision-making by prospective investors.